Pfizer, Inc. has suspended the osteoarthritis clinical program for its investigational drug tanezumab following a request by the FDA based a several reports of tanezumab patients experiencing the worsening of osteoarthritis leading to joint replacement. To date, this adverse event has not been observed in non-osteoarthritis patient populations taking tanezumab. The clinical hold includes the suspension of recruitment of new patients, the dosing of existing patients in the osteoarthritis progr...